/

GALT

Galectin Therapeutics Inc.Pre-market

3.69−0.18 −4.65%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

3.84

Prev close

3.87

Day range

3.673.86

52-week range

2.037.13

Volume

184.33K0.56×

Mkt cap

372.14M

P/E ttm

—

Fwd P/E

-2.20

EPS ttm

-0.4300

Div yield

0.00%

Earnings

—

From 52w high

−48.25%

Price Chart

Yahoo Finance · delayed

GALTOct 13, 2026O 3.84H 3.86L 3.67C 3.69−0.18 (−4.65%)Vol 184.40K

SMA 503.79
SMA 2003.22

1Y change −27.65% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

GALT Galectin Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.86%
1 month: −5.63%
3 months: −30.90%
6 months: +49.39%
Year to date: −11.30%
1 year: −27.65%

Valuation & ownership

Market cap: 372.14M
Enterprise value: 505.02M
P/E (ttm): —
Forward P/E: -2.20
PEG ratio: -36.15
Price / book: —
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.4300
EPS (forward): -1.68
Beta (5y monthly): 0.38
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 100.85M
Float: 47.82M
Short % of float: 11.96%
Short ratio (days): 29.01
Held by insiders: 53.08%
Held by institutions: 15.64%
Avg volume (3m): 329.47K
50-day average: 3.77
200-day average: 3.22
52-week change: −27.65%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 45.2
vs 50-day SMA: −2.53%
vs 200-day SMA: +14.63%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.52%
Realised vol (20d, ann.): 52.6%
From 52-week high: −48.25%
From 52-week low: +81.77%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

11.00

+198.10% implied

Low 11.00Median 11.00High 11.00

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About Galectin Therapeutics Inc.

Yahoo Finance profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Sector: Healthcare
Industry: Biotechnology
Employees: 9
Headquarters: Norcross, GA, United States
Website: galectintherapeutics.com
Officers: Mr. Joel Lewis CPA President & CEO
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary
Dr. Khurram Jamil M.D. Chief Medical Officer
Mr. Robert Tritt J.D. General Counsel

SEAS

Seasonality · GALT

2007–2026 · monthly returns

Strongest month Feb +33.58%Weakest month Nov −7.73%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-32.0	5.3	-6.4	-18.6	11.0	84.1	-36.0	33.0	-1.8	-4.9			−11.3%
2025	-3.1	25.6	-22.3	12.3	-4.4	61.1	72.5	17.6	-0.9	37.0	-1.4	-27.4	+222.5%
2024	1.8	16.0	21.9	46.9	-22.5	-16.9	10.6	8.0	1.9	-10.2	17.0	-55.4	−22.3%
2023	2.7	78.4	1.4	-16.2	-10.8	-8.3	4.2	16.7	9.7	6.3	-4.4	-14.9	+46.9%
2022	-6.8	-3.1	-13.9	-3.7	-16.8	1.6	72.5	-15.9	-14.2	-15.3	-8.0	-11.0	−45.4%
2021	-12.5	14.3	-3.1	103.7	-10.2	-19.4	-14.1	42.9	-1.3	-18.3	-17.0	-21.3	−7.6%
2020	-8.0	-19.4	-7.5	27.0	21.7	1.0	-14.7	1.5	0.8	-4.9	2.4	-13.8	−21.7%
2019	41.1	7.6	-1.9	-16.2	-5.8	3.0	-10.8	-10.0	10.2	8.4	-18.8	-11.5	−16.6%
2018	38.0	-10.8	15.3	-29.7	52.6	25.2	-20.6	28.1	-7.1	-28.3	14.6	-30.6	+2.7%
2017	1.0	91.9	21.1	33.0	-25.8	8.4	-18.7	-14.0	24.4	14.5	-3.7	41.5	+240.8%
2016	-14.0	-9.2	11.7	-0.7	4.2	-0.7	11.6	4.9	-34.3	-36.3	13.9	19.5	−40.2%
2015	-7.2	5.6	-1.5	-10.7	-16.1	8.8	-5.9	-14.0	5.9	16.7	-26.7	-18.0	−52.7%
2014	69.7	23.0	-9.2	-24.6	12.0	6.8	-55.5	2.0	-19.6	7.8	-26.8	-12.6	−57.1%
2013	25.4	32.3	5.6	30.4	-9.2	0.0	40.0	24.2	34.9	4.8	-21.5	-1.5	+294.1%
2012	-15.6	6.2	-21.7	-23.0	-24.8	-12.4	14.1	-7.7	3.2	-14.8	5.3	2.5	−64.4%
2011	37.8	-4.8	-11.9	29.8	0.0	-9.6	-15.6	-15.5	-1.1	3.5	-10.1	20.0	+6.7%
2010	0.0	50.0	4.8	59.1	5.7	-4.1	8.5	-31.2	49.1	-13.9	1.5	30.4	+221.4%
2009	33.3	50.0	22.2	113.6	0.0	-36.2	46.7	-4.5	-21.4	3.0	-14.7	-3.4	+211.1%
2008	-17.1	-29.3	4.9	-9.3	-2.6	-10.5	5.9	-5.6	-41.2	-30.0	-28.6	-10.0	−87.1%
2007	-35.6	313.8	-38.3	14.9	3.5	-60.2	20.0	-16.7	91.4	20.9	-19.8	7.7	+55.6%

INSD

Insider Activity · GALT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

34.48M shares

Sells, 6 months

106.4K shares

Net shares

+34.38M

Net change in insider shares

+179.50%

Date	Insider	Transaction	Shares	Value
Jul 30, 2026	Uihlein Richard EDirector and Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 3.00 - 4.05 per share.	34.38M	$105.81M
Jul 13, 2026	Jamil KhurramOfficer	Sale at price 5.13 per share.	16.3K	$83.28K
Jul 13, 2026	Jamil KhurramOfficer	Conversion of Exercise of derivative security at price 3.04 per share.	16.3K	$49.40K
Jun 28, 2026	Shlevin Harold HDirector	Sale at price 5.00 - 5.04 per share.	30K	$150.89K
Jun 28, 2026	Shlevin Harold HDirector	Conversion of Exercise of derivative security at price 1.23 per share.	30K	$36.90K
Jun 28, 2026	Jamil KhurramOfficer	Sale at price 5.00 - 5.04 per share.	52K	$262.08K
Jun 28, 2026	Jamil KhurramOfficer	Conversion of Exercise of derivative security at price 2.20 - 2.50 per share.	52K	$129.48K
Jun 22, 2026	Jamil KhurramOfficer	Sale at price 3.14 per share.	7.6K	$23.73K
Jun 22, 2026	Jamil KhurramOfficer	Conversion of Exercise of derivative security at price 1.23 per share.	7.6K	$9.29K
May 25, 2026	Jamil KhurramOfficer	Sale at price 3.10 per share.	568	$1.76K
May 25, 2026	Jamil KhurramOfficer	Conversion of Exercise of derivative security at price 1.23 per share.	568	$699
Feb 5, 2026	Eldred Kary N.Director	Purchase at price 2.70 per share.	300	$810
Jan 15, 2026	Uihlein Richard EDirector and Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 3.04 per share.	13.2K	$40.00K
Jan 5, 2026	Lewis JoelChief Executive Officer	Sale at price 3.58 - 4.20 per share.	84K	$321.13K
Jan 5, 2026	Callicutt Jack WChief Financial Officer	Sale at price 3.67 - 4.20 per share.	60K	$233.39K
Jan 5, 2026	Jamil KhurramOfficer	Sale at price 3.65 - 4.20 per share.	60K	$232.40K
Jan 1, 2026	Lewis JoelChief Executive Officer	—	84K	—
Jan 1, 2026	Callicutt Jack WChief Financial Officer	—	60K	—
Jan 1, 2026	Jamil KhurramOfficer	—	60K	—
Dec 30, 2025	Jamil KhurramOfficer	Sale at price 4.07 per share.	8.1K	$33.09K

13F

Investors Holding GALT

latest 13F filings of 29 followed managers

Investors holding GALT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$201.1K	0.00%	43.34K	−71%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

GALT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

GALT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Galectin Therapeutics Inc.

Seasonality · GALT

Insider Activity · GALT

Congress Trades · GALT

Investors Holding GALT

Investors Holding GALT

Congress Trades · GALT

Insider Activity · GALT

Seasonality · GALT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Galectin Therapeutics Inc.

Earnings & Dividends

News